FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362587816> ?p ?o ?g. }

• W4362587816 endingPage "S112" @default.
• W4362587816 startingPage "S111" @default.
• W4362587816 abstract "Stage III non-small cell lung cancer (NSCLC) is highly heterogeneous and often warrants multidisciplinary collaboration. Thus, there is a huge unmet need to understand real-world treatment patterns, and relationship to survival outcomes in stage III NSCLC patients. MOOREA study is a prospective, non-interventional study to assess the real-world treatment patterns and outcomes of Chinese patients with stage III NSCLC. Treatment naïve stage III NSCLC patients were enrolled and assigned to cohort 1 (unresectable) and cohort 2 (resectable). The primary endpoint is treatment pattern, secondary endpoints are progression-free survival, overall survival, and EGFR/ ALK/PD-L1 testing rate. Due to the immaturity of survival endpoints, they will not be reported here. Between July 2019 and February 2022, 437 eligible patients enrolled from 19 centers in China were included in interim analysis (median age 63 years, 32.3% adenocarcinoma). The testing rates for EGFR, ALK, and PD-L1 were 18.1%, 13.3%, and 10.3%, respectively. In Cohort 1, 41.3% (142/344) patients have received chemoradiotherapy (CRT), including 62.7% (89/142) concurrent CRT (cCRT) and 37.3% (53/142) sequential CRT (sCRT). Of patients after cCRT, 52.8% (47/89) further received consolidation therapy, among which 59.6% (28/47) was immunotherapy. For sCRT patients, 34.0% (18/53) received consolidation therapy, with chemotherapy as the majority (44.4%, 8/18). In Cohort 2, all 93 patients have received surgery and 42.4% (39/92) received neoadjuvant therapy (table). Table 125PTreatment patterns in two cohortsCohort 1 (344 pts)TreatmentCRT142/344 (41.3)cCRT89/142 (62.7)Consolidation therapy47/89 (52.8)sCRT53/142 (37.3)Consolidation therapy18/53 (34.0)Cohort 2 (93 pts)Neoadjuvant treatmentYes39/92 (42.4)No53/92 (57.6)Missing, n1Note: data are presented as n/N (%) except specifically notified. Open table in a new tab Note: data are presented as n/N (%) except specifically notified. MOOREA study presents the real-world treatment pattern for stage III NSCLC in China, showing that treatment options for this subset are varied in clinical practice due to disease heterogeneity. Further survival correlations with different treatment patterns are ongoing." @default.
• W4362587816 created "2023-04-06" @default.
• W4362587816 creator A5005114858 @default.
• W4362587816 creator A5006478194 @default.
• W4362587816 creator A5007767638 @default.
• W4362587816 creator A5012381148 @default.
• W4362587816 creator A5017166775 @default.
• W4362587816 creator A5032889063 @default.
• W4362587816 creator A5034474676 @default.
• W4362587816 creator A5039653967 @default.
• W4362587816 creator A5051526968 @default.
• W4362587816 creator A5054023114 @default.
• W4362587816 creator A5056257272 @default.
• W4362587816 creator A5056667302 @default.
• W4362587816 creator A5057415942 @default.
• W4362587816 creator A5059221914 @default.
• W4362587816 creator A5065103624 @default.
• W4362587816 creator A5066360361 @default.
• W4362587816 creator A5074095557 @default.
• W4362587816 creator A5075190002 @default.
• W4362587816 creator A5079532492 @default.
• W4362587816 date "2023-04-01" @default.
• W4362587816 modified "2023-10-03" @default.
• W4362587816 title "125P Real-world treatment patterns in stage III NSCLC patients: Interim results of a prospective, multicenter, non-interventional study (MOOREA)" @default.
• W4362587816 doi "https://doi.org/10.1016/s1556-0864(23)00380-5" @default.
• W4362587816 hasPublicationYear "2023" @default.
• W4362587816 type Work @default.
• W4362587816 citedByCount "0" @default.
• W4362587816 crossrefType "journal-article" @default.
• W4362587816 hasAuthorship W4362587816A5005114858 @default.
• W4362587816 hasAuthorship W4362587816A5006478194 @default.
• W4362587816 hasAuthorship W4362587816A5007767638 @default.
• W4362587816 hasAuthorship W4362587816A5012381148 @default.
• W4362587816 hasAuthorship W4362587816A5017166775 @default.
• W4362587816 hasAuthorship W4362587816A5032889063 @default.
• W4362587816 hasAuthorship W4362587816A5034474676 @default.
• W4362587816 hasAuthorship W4362587816A5039653967 @default.
• W4362587816 hasAuthorship W4362587816A5051526968 @default.
• W4362587816 hasAuthorship W4362587816A5054023114 @default.
• W4362587816 hasAuthorship W4362587816A5056257272 @default.
• W4362587816 hasAuthorship W4362587816A5056667302 @default.
• W4362587816 hasAuthorship W4362587816A5057415942 @default.
• W4362587816 hasAuthorship W4362587816A5059221914 @default.
• W4362587816 hasAuthorship W4362587816A5065103624 @default.
• W4362587816 hasAuthorship W4362587816A5066360361 @default.
• W4362587816 hasAuthorship W4362587816A5074095557 @default.
• W4362587816 hasAuthorship W4362587816A5075190002 @default.
• W4362587816 hasAuthorship W4362587816A5079532492 @default.
• W4362587816 hasBestOaLocation W43625878161 @default.
• W4362587816 hasConcept C121608353 @default.
• W4362587816 hasConcept C126322002 @default.
• W4362587816 hasConcept C143998085 @default.
• W4362587816 hasConcept C146357865 @default.
• W4362587816 hasConcept C151730666 @default.
• W4362587816 hasConcept C166957645 @default.
• W4362587816 hasConcept C188816634 @default.
• W4362587816 hasConcept C203092338 @default.
• W4362587816 hasConcept C2776256026 @default.
• W4362587816 hasConcept C2776694085 @default.
• W4362587816 hasConcept C2776957806 @default.
• W4362587816 hasConcept C2778424827 @default.
• W4362587816 hasConcept C2781182431 @default.
• W4362587816 hasConcept C535046627 @default.
• W4362587816 hasConcept C61943457 @default.
• W4362587816 hasConcept C71924100 @default.
• W4362587816 hasConcept C72563966 @default.
• W4362587816 hasConcept C86803240 @default.
• W4362587816 hasConcept C95457728 @default.
• W4362587816 hasConceptScore W4362587816C121608353 @default.
• W4362587816 hasConceptScore W4362587816C126322002 @default.
• W4362587816 hasConceptScore W4362587816C143998085 @default.
• W4362587816 hasConceptScore W4362587816C146357865 @default.
• W4362587816 hasConceptScore W4362587816C151730666 @default.
• W4362587816 hasConceptScore W4362587816C166957645 @default.
• W4362587816 hasConceptScore W4362587816C188816634 @default.
• W4362587816 hasConceptScore W4362587816C203092338 @default.
• W4362587816 hasConceptScore W4362587816C2776256026 @default.
• W4362587816 hasConceptScore W4362587816C2776694085 @default.
• W4362587816 hasConceptScore W4362587816C2776957806 @default.
• W4362587816 hasConceptScore W4362587816C2778424827 @default.
• W4362587816 hasConceptScore W4362587816C2781182431 @default.
• W4362587816 hasConceptScore W4362587816C535046627 @default.
• W4362587816 hasConceptScore W4362587816C61943457 @default.
• W4362587816 hasConceptScore W4362587816C71924100 @default.
• W4362587816 hasConceptScore W4362587816C72563966 @default.
• W4362587816 hasConceptScore W4362587816C86803240 @default.
• W4362587816 hasConceptScore W4362587816C95457728 @default.
• W4362587816 hasIssue "4" @default.
• W4362587816 hasLocation W43625878161 @default.
• W4362587816 hasOpenAccess W4362587816 @default.
• W4362587816 hasPrimaryLocation W43625878161 @default.
• W4362587816 hasRelatedWork W2059141528 @default.
• W4362587816 hasRelatedWork W2081238229 @default.
• W4362587816 hasRelatedWork W2094558159 @default.
• W4362587816 hasRelatedWork W2277416945 @default.
• W4362587816 hasRelatedWork W2339196520 @default.
• W4362587816 hasRelatedWork W2358156577 @default.
• W4362587816 hasRelatedWork W2392263094 @default.

• next